Matches in SemOpenAlex for { <https://semopenalex.org/work/W2214522079> ?p ?o ?g. }
Showing items 1 to 100 of
100
with 100 items per page.
- W2214522079 endingPage "60" @default.
- W2214522079 startingPage "51" @default.
- W2214522079 abstract "Objectives To compare the efficacy and safety of angiotensin-converting enzyme inhibitors (ACEis) and angiotensin receptor blockers (ARBs) in patients without heart failure. Patients and Methods Meta-analysis of randomized trials identified using PubMed, Embase, and Cochrane Central Register of Controlled Trials searches from January 1, 1980, through April 13, 2015, of ACEis and ARBs compared with placebo or active controls and corroborated with head-to-head trials of ARBs vs ACEis. Outcomes were all-cause mortality, cardiovascular death, myocardial infarction (MI), angina, stroke, heart failure, revascularization, and new-onset diabetes. Results Our search yielded 106 randomized trials that enrolled 254,301 patients. Compared with placebo, ACEis but not ARBs reduced the outcomes of all-cause mortality (ACEis vs placebo: relative risk [RR], 0.89; 95% CI, 0.80-1.00; ARBs vs placebo: RR, 1.01; 95% CI, 0.96-1.06; Pinteraction=.04), cardiovascular death (RR, 0.83; 95% CI, 0.70-0.99 and RR, 1.02; 95% CI, 0.92-1.14; Pinteraction=.05), and MI (RR, 0.83; 95% CI, 0.78-0.90 and RR, 0.93; 95% CI, 0.85-1.03; Pinteraction=.06). The meta-regression analysis revealed that the difference between ACEis and ARBs compared with placebo was due to a higher placebo event rate in the ACEis trials (most of these trials were conducted a decade earlier than the ARB trials) for the outcome of all-cause mortality (P=.001), cardiovascular death (P<.001), and MI (P=.02). Sensitivity analyses restricted to trials published after 2000 revealed similar outcomes with ACEis vs placebo and ARBs vs placebo (Pinteraction>.05). Head-to-head comparison trials of ARBs vs ACEis exhibited no difference in outcomes except for a lower risk of drug withdrawal due to adverse effects with ARBs (RR, 0.72; 95% CI, 0.65-0.81). Conclusion In patients without heart failure, evidence from placebo-controlled trials (restricted to trials after 2000), active controlled trials, and head-to-head randomized trials all suggest ARBs to be as efficacious and safe as ACEis, with the added advantage of better tolerability." @default.
- W2214522079 created "2016-06-24" @default.
- W2214522079 creator A5000758260 @default.
- W2214522079 creator A5021945153 @default.
- W2214522079 creator A5035850344 @default.
- W2214522079 creator A5043251635 @default.
- W2214522079 creator A5057739373 @default.
- W2214522079 creator A5061848647 @default.
- W2214522079 date "2016-01-01" @default.
- W2214522079 modified "2023-10-05" @default.
- W2214522079 title "Angiotensin-Converting Enzyme Inhibitors or Angiotensin Receptor Blockers in Patients Without Heart Failure? Insights From 254,301 Patients From Randomized Trials" @default.
- W2214522079 cites W190027148 @default.
- W2214522079 cites W1995662581 @default.
- W2214522079 cites W2000442546 @default.
- W2214522079 cites W2054796764 @default.
- W2214522079 cites W2079213131 @default.
- W2214522079 cites W2106343349 @default.
- W2214522079 cites W2107328434 @default.
- W2214522079 cites W2107391935 @default.
- W2214522079 cites W2111421663 @default.
- W2214522079 cites W2142935346 @default.
- W2214522079 cites W2143465004 @default.
- W2214522079 cites W2152798629 @default.
- W2214522079 cites W2160359845 @default.
- W2214522079 cites W2161392015 @default.
- W2214522079 cites W2169506520 @default.
- W2214522079 cites W2305118939 @default.
- W2214522079 doi "https://doi.org/10.1016/j.mayocp.2015.10.019" @default.
- W2214522079 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/26763511" @default.
- W2214522079 hasPublicationYear "2016" @default.
- W2214522079 type Work @default.
- W2214522079 sameAs 2214522079 @default.
- W2214522079 citedByCount "78" @default.
- W2214522079 countsByYear W22145220792016 @default.
- W2214522079 countsByYear W22145220792017 @default.
- W2214522079 countsByYear W22145220792018 @default.
- W2214522079 countsByYear W22145220792019 @default.
- W2214522079 countsByYear W22145220792020 @default.
- W2214522079 countsByYear W22145220792021 @default.
- W2214522079 countsByYear W22145220792022 @default.
- W2214522079 countsByYear W22145220792023 @default.
- W2214522079 crossrefType "journal-article" @default.
- W2214522079 hasAuthorship W2214522079A5000758260 @default.
- W2214522079 hasAuthorship W2214522079A5021945153 @default.
- W2214522079 hasAuthorship W2214522079A5035850344 @default.
- W2214522079 hasAuthorship W2214522079A5043251635 @default.
- W2214522079 hasAuthorship W2214522079A5057739373 @default.
- W2214522079 hasAuthorship W2214522079A5061848647 @default.
- W2214522079 hasConcept C126322002 @default.
- W2214522079 hasConcept C127413603 @default.
- W2214522079 hasConcept C142724271 @default.
- W2214522079 hasConcept C164705383 @default.
- W2214522079 hasConcept C168563851 @default.
- W2214522079 hasConcept C204787440 @default.
- W2214522079 hasConcept C27081682 @default.
- W2214522079 hasConcept C2778198053 @default.
- W2214522079 hasConcept C2780645631 @default.
- W2214522079 hasConcept C44249647 @default.
- W2214522079 hasConcept C500558357 @default.
- W2214522079 hasConcept C71924100 @default.
- W2214522079 hasConcept C78519656 @default.
- W2214522079 hasConcept C82789193 @default.
- W2214522079 hasConcept C95190672 @default.
- W2214522079 hasConceptScore W2214522079C126322002 @default.
- W2214522079 hasConceptScore W2214522079C127413603 @default.
- W2214522079 hasConceptScore W2214522079C142724271 @default.
- W2214522079 hasConceptScore W2214522079C164705383 @default.
- W2214522079 hasConceptScore W2214522079C168563851 @default.
- W2214522079 hasConceptScore W2214522079C204787440 @default.
- W2214522079 hasConceptScore W2214522079C27081682 @default.
- W2214522079 hasConceptScore W2214522079C2778198053 @default.
- W2214522079 hasConceptScore W2214522079C2780645631 @default.
- W2214522079 hasConceptScore W2214522079C44249647 @default.
- W2214522079 hasConceptScore W2214522079C500558357 @default.
- W2214522079 hasConceptScore W2214522079C71924100 @default.
- W2214522079 hasConceptScore W2214522079C78519656 @default.
- W2214522079 hasConceptScore W2214522079C82789193 @default.
- W2214522079 hasConceptScore W2214522079C95190672 @default.
- W2214522079 hasIssue "1" @default.
- W2214522079 hasLocation W22145220791 @default.
- W2214522079 hasLocation W22145220792 @default.
- W2214522079 hasOpenAccess W2214522079 @default.
- W2214522079 hasPrimaryLocation W22145220791 @default.
- W2214522079 hasRelatedWork W1539974851 @default.
- W2214522079 hasRelatedWork W1859326399 @default.
- W2214522079 hasRelatedWork W1966127473 @default.
- W2214522079 hasRelatedWork W1974781192 @default.
- W2214522079 hasRelatedWork W2074965717 @default.
- W2214522079 hasRelatedWork W2085650940 @default.
- W2214522079 hasRelatedWork W2119160676 @default.
- W2214522079 hasRelatedWork W2383994333 @default.
- W2214522079 hasRelatedWork W588655279 @default.
- W2214522079 hasRelatedWork W642714463 @default.
- W2214522079 hasVolume "91" @default.
- W2214522079 isParatext "false" @default.
- W2214522079 isRetracted "false" @default.
- W2214522079 magId "2214522079" @default.
- W2214522079 workType "article" @default.